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SUM1'1ARY 
The human c-erbB-2 protooncogene product (erbB-2 protein) is 
a 185 kilodalton glycoprotein closely related to epidermal 
growth factor receptor protein. In this study, we measured the 
concentration of circulating erbB-2 protein in cancer patients 
by means of a new immunoradiometrj-c assay (IRMA) Two monoclonal 
antibodies (MoAbs ) , SV2-6ly and 6Gl0, recognize erbB-2 protein 
but bind to separate epitopes . SV2-6ly was used as an 
immunoadsorbent and 6Gl0 as an 125I-labeled probe . A serum was 
considered positive for erbB-2 protein if the percent binding 
exceeded the mean of the normal group by more than 3 standard 
deviations . Eleve n of 21 patients with advanced breast cancer 
and 1 of 15 with advanced gastric cancer were positive. Serum 
erbB - 2 protei n levels correlated well with the therapy and the 
status of t he patients with breast cancer . On the contrary , all 
patients with advanced colon , ovarian , or pancreatic cancers , 
showed levels below the cutoff value . These results suggest that 
circulating erbB - 2 protein can be measured using the newly 
constructed IRMA . Since c-erbB-2 protooncogene amplification and 
overexpression are accepted as a good marker of aggressiveness, 
relapsing potency , and poor prognosis , this IRMA should be a 
promising tool with which to help manage breast cancer patients . 
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INTRODUCTION 
The c-erbB-2 protooncogene encodes a protein that is similar 
to the epidermal growth factor (EGF) receptor but is distinct 
from it.1) 
Recently we reported that the c-erbB-2 protooncogene product 
( erbB-2 protein) , overexpressed on the surface membranes of 
va·rious adenocarcinomas, is a useful target in 
immunoscintigraphy using monoclonal antibodies (MoAbs) .2) This 
protein is reportedly expressed in various adenocarcinomas 
including breast, gastric , colon cancers , 3) whereas EGF 
receptors are expressed on squamous cell carcinomas and gliomas 
as well as adenocarcinomas.4-6) Amplification and overexpression 
of the c-erbB-2 gene correlate with tumor aggressiveness and 
unfavorable clinical outcome, especially in patients with breast 
or gastric cancer . 7 - 1 1) In addition, this protein is detectable 
in the sera of breast cancer patients . 3 , 12) In this study , we 
constructed an immunoradiometric assay (IRMA) to determine 
whether circulating erbB-2 protein is detectable in the sera of 




MATERIALS AND METHODS 
Monoclonal Antibodies 
MoAbs SV2-61y and 6G10 (N' h' · lC 1re1, Tokyo, Japan) recognize 
the extracellular domains of erbB-2 prote 1·n, d b' an 1nd separate 
epitopes · SV2-61y (IgG1) was generated by immunizing mice with 
SV11 cells in which the c-erbB-2 complementary DNA was 
expressed . 13) The MoAb 6G10 (IgG2a) was obtained by immunizing 
mice vlith recombinant c-erbB-2 gene transfected A4 cells.3) 
Standard antigens 
Standard antigens were bt · d b o a1ne y solubilizing the cell 
membrane of A4 (c e bB 2 t f - r - rans ected NIH3T3) cells cultured in 
Eagle ' s minimum essential medium (Nissui Pharmaceutical Co . , 
Tokyo) supplemented with 10% fetal calf serum and 0. 03% L-
' g lutamine. The cells t 1 were ransp anted subcutaneously to a 
BALB/c - nu/nu mouse , then 2 weeks later, the A4 xenograft was 
removed . Cells were obtained by passing tumor specimens through 
a stainless steel mesh and were suspended in phosphate buffered 
saline (PBS) .. After adding 4ml 0. 5% Triton X-100 ·in PBS, 
cells were incubated on ice for 1 h. · Nuclel and debris were 
removed by centrifugation (10000 x g , 10 min). The supernatant 
was serially diluted with dilution buffer (Daiichi Radioisotope 
Laboratories Ltd ., Tokyo, Japan) and the antigen . level of the 
supernatant diluted to 1/8 was defined as SOOU/ml arbitrarily. 
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Preparation of beads 
Polystyrene beads (7mm in diameter) were coated with MoAb 
SV2-6ly in 1mM phosphate buffer, pH6.4 containing 5% MoAb at 4°C 
for 20 h. After washing the beads three times with distilled 
water, non-specific binding was blocked by processing in 50mM 
PBS containing 0.5% bovine serum,albumin (BSA). 
Radio-iodination of monoclonal antibody 
MoAb 6G10 was radio-iodinated using the chloramine-T method . 
Purified antibody (20~g) in 0 . 3M phosphate buffer , pH7. 5 and 
125I (0. 4mCi) for protein labeling (Amersham International plc , 
Buckinghamshire , UK) was mixed with 2 . 5 ~g of chloramine-T 
(Nakarai Chemicals, Kyoto, Japan) . After a 5 min incubation, 
125I-labeled MoAb was separated from free 125I through a 
Sephadex G-25 gel . The specific activity was 444MBq(12mCi)/mg . 
Sera 
Sera were obtained between 1989 and 1990 in Kyoto University 
Hospital from patients with breast cancer (n=21) ovarian 
cancer (n=11), colon cancer {n=15) , gastric cancer (n=15), and 
pancreatic cancer (n=10). Serum samples were stor~d at -2 0°C 
until use. All cancer patients underwent treatment in Kyoto 
University Hospital, and diagnoses were based upon surgical 
and/or histological findings . Clinical examinations , laboratory 
tests, and radiological findings demonstrated that all of them 
were in Stage IV or the recurrent stage, at the time of serum 
sampling. Sera were also taken from 20 normal adults ; 10 males 
\' 
and 10 females . 
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Immunoradiometric assay(IRMA) 
An IRMA was constructed using SV2-61y as the immunoadsorbent 
125 d b Rad]_. a-iodinated 6Gl0 was and 6G10 as the I-labele pro e. 
· 1 · b ff (Oal· ichi Radioisotope dilut~ed with tracer dl utlon u er 
J ) at a specific activity of Laboratories, Ltd., Tokyo, apar; 
60000cpm/100~l l . Fifty microliters of standard antigens or serum 
W]_'th 100 Il l of 125I-labeled 6Gl0 and SV2-samples were incubated r 
6 h at room temperature . After washing the 6ly-coated beads for 
· 'th dl"stl'lled water, the radioactivity bound beads three tlmes wl 
to the beads were measured using a well-gamma counter. Bound 
· · was converted t~ erbB-2 protein U/ml by reference radioactlvlty 
to 9 standard curve . 
CA15--3 assay 
In all the patients with breast cancer, the serum CA15-3 
14 15 ) · d usl'ng a commercially available kit , l evels were determlne 
(Cent ocor , Malvern, PA, USA ) with a cutoff value of 28U/ml . The 
procedure of the assay was as described by the manufacturer . 
CA15-·3 levels Were Compared with those of erbB-2 protein . 
RESULTS 
The standard curve of the assay is shown in Fig· 1 . The 
prozone phenomenon was observed with the less diluted 
supernatant of the standard antigens. Two of the serum samples 
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were diluted with dilution buffer in the geometrical 'series, and 
the erbB-2 protein levels of diluted samples are illustrated in 
Fig. 2. Both of the plots showed good linearity from 1 to 1/32 
dilution. In the 20 healthy controls, the erbB-2 protein 
concentrations ranged from 0 to 2. 6U/ml. The mean and the 
standard deviation was 0.4 and 0.7, respectively, and there was 
no difference between males and females. The cutoff value was 3 
U/ml, determined as a mean plus 3 standard deviations. All the 
healthy controls showed levels below the cutoff value (Fig. 3). 
Twelve of 21 patients (57 .1%) with advanced breast cancer were 
positive. On the contrary, all 15 patients with colon cancer, 
all 11 patients with ovarian cancer, all 10 patients with 
pancreatic cancer, and 14 of 15 patients with gastric cancer had 
erbB-2 protein levels below the cutoff value of 3U/ml. 
Fifteen of 21 patients (71. 4%) had positive CA15-3 levels 
with a cutoff level of 28U/ml. The patients were divided into 
four groups on the basis of erbB-2 protein and CAlS-3 levels 
(Table I). The correlation coefficient between erbB-2 protein 
and CAlS-3 was 0.425. 
Serum samples were serially taken from 2 patients (A and B) 
with breast cancer, and the changes of serum, erbB-2 protein 
levels and CA15-3 levels were determined. Patient A, a 53-year-
old female, who had undergone left mastectomy 2 years 
previously, had multiple liver metastases, bone metastases, lung 
l 
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lymphangitis carcinomatosa and ascites. Liver metastases r...;ere 
treated by transcatheter arterial chemoinfusion and 
embolization, after which, the serum erbB-2 protein level 
decreased. However, the erbB-2 protein levels increased again in 
accoJ~dance with the extension of metastatic lesions. She expired 
11 months after the diagnosis of recurrence (Fig. 4). Patient B, 
I 
a 52--year-old female with left breast cancer, had multiple bone, 
bone marrow and brain metastases at the time of the first 
consultation, and mastectomy was not performed. During 
admission, she was treated by chemotherapy using fluorouracil, 
cyclophosphamide and tamoxifen citrate. Metastatic lesions 
improved and the serum erbB-2 protein level decreased (Fig. 5). 
In both patients, serum erbB-2 protein levels determined by 
our IRMA changed in parallel with serum CAlS-3 in response to 
the therapy and the status of patients. 
DISCUSSION 
The protooncogene c-erbB-2 encodes a 185 kilodalton 
transmembrane tyrosine kinase, which is similar to epidermal 
growth factor (EGF) receptor, although EGF does not bind to nor 
activate erbB-2 protein. Recently heregulin (l{RG) proteins 
interacting specifically with e~bB-2 proteiri have been 
i d en t i f i e d a s t he p rob a b 1 e .nat u r a 1 1 i g an d s f o r e r b B - 2 
protein .16) 
Overexpression of the erbB-2 protein, generally as a 
I 
consequence of gene amplification, has been reported in human 
breast, gastric, ovarian, colon, pancreatic, and urinary bladder 
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cancers. Some clinical studies have disclosed association of c-
erbB-2 gene amplification and aggressiveness, relapsing potency 
and poor prognosis of these cancers. 7-11,17-20) 
In this study , we detected and quantified erbB-2 prote in i n 
sera from patients with adenocarcinomas . Patients with br e a st 
cancer had high concentrations an? positive rates compared with 
other adenocarcinoma patients. According to some immu n o-
histochemical reports, about 30% of breast cancer patients ha d 
erbB-2 protein .21, 22) An immunohistochemical st u dy has show n 
that 28 (14 . 3% ) of 196 advanced gastric cancer cases were 
positively stained for erbB-2 protein . 11 ) In our study , 57.1 and 
6. 7% of breast and gastric cancer patients , respectively , had 
positive serum erbB-2 protein . Our breast cancer patients 
demonstrated a higher positive rate than those studied 
immunohistochemically and reported elsewhere . This may be 
because all our patients were in the advanced stages. Yu et al. 
reported 45 . 7% of the postoperative recurrent breast ca n ce r 
patients were positive serum erbB-2 protein. 12 ) Their positive 
rate may be considered equvalent to that of our advanced cancer 
patients . 
CAl 5-3 , a tumor marker detectable by two mono c l o nal 
t · b d · 11508 and DF3 has been used for the .diagnosis an d an l o les , 
follow-up of breast cancer patients. The positive rate of CA15 - 3 
in advanced stages is reported to be 70% . 23 , 2 4 ) In our stu dy , 
57.1% of advanced breast cancer patients had positive serum 
erbB-2 protein levels , while 71.4% of them showed positive CA15 -
3 . Furthermore, erbB-2 protein represented only a weak 
c o rrelatio n with CA15-3. One patient showed positive erbB - 2 
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protein and negative CA15-3, and 4 patients were with negative 
erbB-2 protein and positive CA15-3. Thus, erbB-2 protein is not 
only biochemically a completely distinct substance from the 
antigen determined with CA15-3 assay, but it may be considered 
as a different tumor marker from CA15-3 in monitoring breast 
ca n cer patients . Further studx with more patients must be 
u ndertake n to estimate the usefulness of this erbB-2 protein 
assay in comparison with CA15-3 . 
Ge n e amplification and overexpression of the c-erbB-2 have 
clinically prognostic significance for paitents with c-erbB-2 
p o~; i ti ve t umor s. Thus , gene analyzing and immunohistochemical 
tests are essential in defining an individual prognosis . 
I 
Hov,,ever , the s e tests need tumor specimens , cost a lot of time 
and labor , and cannot deal with many samples in a short time. 
Compared wit h them , IRMA , a highly simpler method, has several 
advan tages ; patient ' s serum can be obtained easily and 
repeatedly , many samples are measured at the same time , and IRMA 
c an q u a ntify them nu merically . In addition , our construction of 
IRMA measuring oncogene product suggests that other oncogene 
products can be dete r mined with IRMA, and such serodiagnoses may 
supplement or replace the gene analyzing and immunohistochemical 
t ests in some clinical practices . Although additional studies, 
including patients in the earlier stages , will be necessary to 
. . 
evaluate the predictive value of serum erbB-2 proteln, our IRMA 
for erbB-2 protein seems to be a useful tool . with which to 
monitor breast cancer patients . 
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. Legends 
Fig.1. Standard curve. Bars indicate the standard deviations of 
five different assays. cpm: radioactivity of the beads. 
Fig . 2. Two samples of erbB-2 protein positive serum were diluted 
and measured by the IRMA. 
Fig . 3 . Serum c-erbB-2 product levels in healthy controls and 
adenocarinoma patients . One large • 
patients . 
indicates ten 
Fig.4 . Patient A. 53 year-old female with breast cancer showing 
liver , lu n g, and bone · metastases. TAE: transcatheteral 
arterial embolization of metastatic liver lesions. 
Serum erbB-2 protein levels( e ); CA15-3 levels(O ) . 
Fig.S . Patient B . 52 year-old female breast cancer patients with 
bone and bone marrow metastases. Chemotherapy continued 
for 3 months in hospital . Serum erbB-2 protein 
levels (e); CA15-3 levels ( 0 ). 
f,',g ./ 8000 
7000 
Table I. Relationship between erbB-2 Protein and CAlS-3 Levels 6000 
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